Prognostic impact of the new P2Y12 (ticagrelor and prasugrel) versus clopidogrel in acute coronary syndrome patients in relation to renal function

Back

ESC Premium Access

Prognostic impact of the new P2Y12 (ticagrelor and prasugrel) versus clopidogrel in acute coronary syndrome patients in relation to renal function

Session: Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal?

Topic: Pharmacotherapy

Speaker: Mrs M. Castineira Busto (Vigo, ES)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Mrs Maria Castineira Busto

University Hospital Alvaro Cunqueiro, Vigo (Spain)

0 follower

5 more presentations in this session

Type of P2Y12 inhibitor at the acute stage and one-year mortality in acute myocardial infarction. The FAST-MI programme

Speaker: Professor N. Danchin (Paris, FR)

A head-to-head comparison of uniform prasugrel treatment vs. clopidogrel treatment for confirmed responders in acute coronary syndrome patients: results from the randomized TROPICAL-ACS trial

Speaker: Doctor R. Hein (Munich, DE)

Prasugrel vs Ticagrelor in patients with acute coronary syndrome and diabetes: a propensity match substudy of RENAMI

Speaker: Doctor M. Bertaina (Turin, IT)

Next generation P2Y12 inhibitors improve survival in ACS: An analysis from the British Cardiovascular Intervention Society database.

Speaker: Doctor H. Contractor (Manchester, GB)

The OPTIDUAL trial: long term follow-up

Speaker: Professor G. Helft (Paris, FR)

Access

Abstract

Video

Access the full session

Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal?

Speakers: Mrs M. Castineira Busto, Professor N. Danchin, Doctor R. Hein, Doctor M. Bertaina, Doctor H. Contractor...

Access

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources